{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T05:43:30Z","timestamp":1747979010350,"version":"3.37.3"},"reference-count":26,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"5","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":193,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>One mechanism involved in the pathophysiology of posttraumatic stress disorder (PTSD) is increased noradrenergic stimulation. Prazosin, a commonly utilized treatment for PTSD nightmares, works to block noradrenergic stimulation of the alpha-1 adrenoreceptor. Dual antagonism of this receptor would be expected to increase risk of adverse effects. Carvedilol has both alpha-1 adrenergic and nonselective beta-adrenoreceptor antagonist activity. To our knowledge, there is no clinical guidance on use of prazosin in patients concomitantly prescribed carvedilol for hypertension. This case describes the successful titration of prazosin for PTSD symptoms in a 49-year-old male concurrently prescribed carvedilol for hypertension. This patient had a previous unsuccessful prazosin trial due to adverse effects. His second trial of prazosin was efficacious and well tolerated using individualized titration with close monitoring by mental health clinical pharmacy specialists in the pharmacist-managed prazosin titration clinic. This case details the importance of utilizing caution and close follow-up in prazosin dose titration in patients prescribed concomitant alpha-1 antagonists. This appears to be the first case report describing the successful dose titration of prazosin for PTSD in a patient on a concurrent alpha-1 antagonist antihypertensive agent.<\/jats:p>","DOI":"10.9740\/mhc.2019.09.326","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T20:12:51Z","timestamp":1567627971000},"page":"326-330","source":"Crossref","is-referenced-by-count":2,"title":["Prazosin initiation and dose titration in a patient with posttraumatic stress disorder on concurrent carvedilol"],"prefix":"10.9740","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-0252","authenticated-orcid":false,"given":"Chelsea","family":"Khaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8016-7040","authenticated-orcid":false,"given":"Tami","family":"Argo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"key":"2020060307345575800_i2168-9709-9-5-326-b01","first-page":"591","article-title":"Neurocognitive disorders","author":"American Psychiatric Association","year":"2013","journal-title":"Diagnostic and statistical manual of mental disorders. 5th ed"},{"issue":"4","key":"2020060307345575800_i2168-9709-9-5-326-b02","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/archpsyc.1993.01820160036003","article-title":"Abnormal noradrenergic function in posttraumatic stress disorder","volume":"50","author":"Southwick","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"2020060307345575800_i2168-9709-9-5-326-b03","doi-asserted-by":"crossref","unstructured":"Friedman\n              MJ\n            . \n          Posttraumatic and acute stress disorders. 6th ed. New York: Springer Publishing Co;2015.","DOI":"10.1007\/978-3-319-15066-6"},{"issue":"9","key":"2020060307345575800_i2168-9709-9-5-326-b04","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1176\/appi.ajp.2013.12081133","article-title":"A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan","volume":"170","author":"Raskind","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"8","key":"2020060307345575800_i2168-9709-9-5-326-b05","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.biopsych.2006.06.032","article-title":"A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder","volume":"61","author":"Raskind","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"2","key":"2020060307345575800_i2168-9709-9-5-326-b06","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1176\/appi.ajp.160.2.371","article-title":"Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study","volume":"160","author":"Raskind","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"2","key":"2020060307345575800_i2168-9709-9-5-326-b07","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jpsychores.2011.11.010","article-title":"Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US Military Veterans","volume":"72","author":"Germain","year":"2012","journal-title":"J Psychosom Res"},{"issue":"8","key":"2020060307345575800_i2168-9709-9-5-326-b08","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2146\/ajhp070124","article-title":"Prazosin for treatment of nightmares related to posttraumatic stress disorder","volume":"65","author":"Taylor","year":"2008","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"2020060307345575800_i2168-9709-9-5-326-b09","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/0891988703256050","article-title":"Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder","volume":"16","author":"Peskind","year":"2003","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"19","key":"2020060307345575800_i2168-9709-9-5-326-b10","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2020060307345575800_i2168-9709-9-5-326-b11","unstructured":"Furmaga\n              E\n            , GeraciM.\n          Alpha-blocker combination therapy in PTSD and BPH. Washington: Pharmacy Benefits Management Services, Medical Advisory Panel and VISN Pharmacist Executives, Veterans Health Administration, Department of Veterans Affairs;2012."},{"issue":"4","key":"2020060307345575800_i2168-9709-9-5-326-b12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/BF02244985","article-title":"Binding of antidepressants to human brain receptors: focus on newer generation compounds","volume":"114","author":"Cusack","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"2020060307345575800_i2168-9709-9-5-326-b13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"issue":"Suppl 1","key":"2020060307345575800_i2168-9709-9-5-326-b14","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1097\/00005344-199219001-00005","article-title":"Alpha 1-blocking properties of carvedilol during acute and chronic administration","volume":"19","author":"Giannattasio","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"2020060307345575800_i2168-9709-9-5-326-b15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4172\/2167-1095.1000104","article-title":"Drugs and orthostatic hypotension: evidence from literature","volume":"1","author":"Milazzo","year":"2012","journal-title":"J Hypertens"},{"key":"2020060307345575800_i2168-9709-9-5-326-b16","unstructured":"Stahl\n              SM\n            . \n          The prescriber's guide: Stahl's essential psychopharmacology. 4th ed. Cambridge: Cambridge University Press;2011."},{"year":"2009","key":"2020060307345575800_i2168-9709-9-5-326-b17","article-title":"Prazosin [package insert]"},{"key":"2020060307345575800_i2168-9709-9-5-326-b18","unstructured":"Clozapine [package insert]. East Hanover (NJ): Novartis Pharmaceuticals; 2014."},{"year":"2003","key":"2020060307345575800_i2168-9709-9-5-326-b19","article-title":"Quetiapine [package insert]"},{"year":"2011","key":"2020060307345575800_i2168-9709-9-5-326-b20","article-title":"Mirtazapine [package insert]"},{"key":"2020060307345575800_i2168-9709-9-5-326-b21","unstructured":"Trazodone [package insert]. Chestnut Ridge (NY): Par Pharmaceutical; 2017."},{"key":"2020060307345575800_i2168-9709-9-5-326-b22","unstructured":"Carvedilol [package insert]. Research Triangle Park (NC): GlaxoSmithKline LLC; 2007."},{"key":"2020060307345575800_i2168-9709-9-5-326-b23","unstructured":"Popish\n              SJ\n            , MontanoM, HargroveS, MaieritschK, LiK, FarhadianS, et al. \n          A VA clinician's guide to managing posttraumatic stress disorder. Washington: US Department of Veterans Affairs, Pharmacy Benefits Management, National Academic Detailing Service;2019."},{"issue":"6","key":"2020060307345575800_i2168-9709-9-5-326-b24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1507598","article-title":"Trial of prazosin for post-traumatic stress disorder in military veterans","volume":"378","author":"Raskind","year":"2018","journal-title":"N Engl J Med"},{"key":"2020060307345575800_i2168-9709-9-5-326-b25","unstructured":"The Management of Posttraumatic Stress Disorder Work Group. VA\/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. Version 3.0. Washington: Veterans Health Administration and Department of Defense;2017."},{"key":"2020060307345575800_i2168-9709-9-5-326-b26","unstructured":"National Institute for Health and Care Excellence. Post traumatic stress disorder (NICE Guideline 116) 2018[cited 2019 Feb 4]. Available at: https:\/\/www.nice.org.uk\/guidance\/ng116"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/9\/5\/326\/2427742\/mhc_2019_09_326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/9\/5\/326\/2427742\/mhc_2019_09_326.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:25:54Z","timestamp":1731687954000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/9\/5\/article-p326.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2019.09.326","relation":{},"ISSN":["2168-9709"],"issn-type":[{"type":"electronic","value":"2168-9709"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}